Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $8.50.

Several brokerages have recently commented on AUTL. Truist Financial upgraded Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. HC Wainwright assumed coverage on Autolus Therapeutics in a research note on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Friday. Finally, Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th.

Key Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Company reiterated 2026 guidance: management expects AUCATZYL® net product revenue of $120–$135M and a shift to positive gross margin in 2026 — a clear path to improving unit economics and cash-generation visibility. Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
• Positive Sentiment: Commercial traction: AUCATZYL reported ~$23.3M net product revenue in Q4 and $74.3M for FY2025; UK launch underway after positive NICE evaluation and real‑world data show favorable activity/safety — supports revenue ramp thesis. Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades/price target upside: Needham reaffirmed a Buy with a $10 PT (large theoretical upside from current levels) and Truist upgraded to Strong-Buy — these notes can attract speculative buying ahead of clinical readouts. Benzinga
• Neutral Sentiment: Pipeline catalyst timeline: pivotal Phase 2 trials enrolling in lupus nephritis and pediatric ALL; initial BOBCAT Phase 1 data in progressive MS expected late 2026 — potential upside but not immediate. Press Release
• Neutral Sentiment: Company hosted an earnings call and published the transcript/slides — useful for detail on margin assumptions and cash runway into Q4 2027. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics: Q4 EPS of ($0.34) missed consensus ($0.27); company still deeply unprofitable with a large negative net margin and negative ROE — these metrics pressure sentiment in the near term. Press Release / Slide Deck
• Negative Sentiment: Analyst caution: Some outlets (and at least one analyst note) highlight a challenging risk/reward despite strong B-ALL data, citing reliance on upcoming autoimmune and pediatric data to re‑rate the stock. Seeking Alpha Hold-perspective

Autolus Therapeutics Stock Down 6.2%

NASDAQ:AUTL opened at $1.21 on Friday. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $2.70. The firm has a 50 day moving average of $1.49 and a 200 day moving average of $1.52. The stock has a market capitalization of $322.03 million, a price-to-earnings ratio of -1.12 and a beta of 1.95.

Autolus Therapeutics (NASDAQ:AUTL) last announced its earnings results on Friday, March 27th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The firm had revenue of $24.29 million during the quarter, compared to analyst estimates of $23.92 million. As a group, analysts expect that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AUTL. Mak Capital One LLC boosted its holdings in Autolus Therapeutics by 15.3% in the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after purchasing an additional 3,987,727 shares during the last quarter. Armistice Capital LLC raised its stake in shares of Autolus Therapeutics by 12.2% during the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after buying an additional 1,900,000 shares during the last quarter. TFG Asset Management GP Ltd lifted its holdings in shares of Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after buying an additional 900,000 shares during the period. Schroder Investment Management Group lifted its holdings in shares of Autolus Therapeutics by 12.5% in the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock valued at $18,694,000 after buying an additional 1,056,092 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of Autolus Therapeutics by 108.1% in the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock worth $3,308,000 after buying an additional 1,054,458 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.